- Trial phase
- Approved (EU/UK/Japan); Filed/PDUFA review in US
- Time to market
- Already marketed in the EU (European Commission approval June 2025) and UK (MHRA approval) under Santen's commercial operations. Launched in Japan as RYJUSEA in April 2025. US approval timeline uncertain after the CRL and pending tomorrow's AdComm.
- Why 3/10
- Ryjunea is already approved and commercializing in the EU, UK, and Japan. The next catalyst is the FDA Advisory Committee meeting on October 30, 2026 for US approval, but Ligand holds only EMEA royalty rights (acquired for $23M) and Ryjunea is one of over 200 assets in Ligand's diversified royalty portfolio. With no hard binary catalyst that drives LGND's share price, impactScore is 3.
The FDA Dermatologic and Ophthalmic Drugs Advisory Committee meets October 30, 2026 to review SYD-101/Ryjunea for US approval. FDA briefing documents released October 28 question the drug's efficacy at slowing myopia progression. An unfavorable AdComm vote would likely keep Ryjunea out of the US market indefinitely; a favorable vote would still face an FDA decision. For LGND this catalyst matters less than for Sydnexis since Ligand holds only EMEA royalty rights.
Price Chart
Executive Summary
Ryjunea (atropine sulfate 0.01%) is a low-dose atropine eye drop approved in the EU, UK, and Japan to slow pediatric myopia progression. Ligand Pharmaceuticals (LGND) acquired EMEA royalty rights from developer Sydnexis for $23 million in September 2026, receiving a tiered low-double-digit to high-teens royalty on EMEA sales. The FDA previously issued a Complete Response Letter in October 2025, and the advisory committee meeting scheduled for October 30, 2026 just one day from now faces skeptical FDA briefing documents questioning efficacy. For LGND, this is a small, non-core royalty interest among more than 200 portfolio assets.
How It Works
A nightly low-dose atropine eye drop that relaxes the eye's focusing muscle, which helps slow the worsening of nearsightedness (myopia) in children. Atropine is a well-known anticholinergic drug; at this very low concentration (0.01%) it reduces progression of eyeball elongation without causing the severe side effects of higher doses.
Trial Status
The pivotal Phase 3 STAR trial (847 patients) met its primary endpoint (proportion with confirmed myopia progression of -0.75D) and key secondary endpoint (annual progression rate). Data were presented at AMCP Nexus 2025 and AAPOS 2026. Despite meeting endpoints, the FDA issued a Complete Response Letter in October 2025 stating the data did not sufficiently demonstrate effectiveness. The FDA has since scheduled an Advisory Committee meeting for October 30, 2026.
The Two-Sided Case
Upcoming Catalysts
- FDA Dermatologic and Ophthalmic Drugs Advisory Committee meeting for SYD-101/Ryjunea on October 30, 2026 (tomorrow)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report